ATE347599T1 - Tuberkulose impfstoff - Google Patents

Tuberkulose impfstoff

Info

Publication number
ATE347599T1
ATE347599T1 AT98947427T AT98947427T ATE347599T1 AT E347599 T1 ATE347599 T1 AT E347599T1 AT 98947427 T AT98947427 T AT 98947427T AT 98947427 T AT98947427 T AT 98947427T AT E347599 T1 ATE347599 T1 AT E347599T1
Authority
AT
Austria
Prior art keywords
nucleic acid
acid molecules
present
tuberculosis vaccine
novel recombinant
Prior art date
Application number
AT98947427T
Other languages
German (de)
English (en)
Inventor
Stefan H E Kaufmann
Juergen Hess
Original Assignee
Max Planck Gesellschaft
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Max Planck Gesellschaft filed Critical Max Planck Gesellschaft
Application granted granted Critical
Publication of ATE347599T1 publication Critical patent/ATE347599T1/de

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/195—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from bacteria
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/195—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from bacteria
    • C07K14/35—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from bacteria from Mycobacteriaceae (F)
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
    • C12N15/62—DNA sequences coding for fusion proteins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/01—Fusion polypeptide containing a localisation/targetting motif
    • C07K2319/02—Fusion polypeptide containing a localisation/targetting motif containing a signal sequence
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/40—Fusion polypeptide containing a tag for immunodetection, or an epitope for immunisation

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Genetics & Genomics (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Molecular Biology (AREA)
  • General Health & Medical Sciences (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Biomedical Technology (AREA)
  • Medicinal Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biotechnology (AREA)
  • General Engineering & Computer Science (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Wood Science & Technology (AREA)
  • Zoology (AREA)
  • Physics & Mathematics (AREA)
  • Plant Pathology (AREA)
  • Microbiology (AREA)
  • Oncology (AREA)
  • Public Health (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Communicable Diseases (AREA)
  • Veterinary Medicine (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Peptides Or Proteins (AREA)
AT98947427T 1997-08-22 1998-08-12 Tuberkulose impfstoff ATE347599T1 (de)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
EP97114614A EP0902086A1 (en) 1997-08-22 1997-08-22 Tuberculosis vaccine

Publications (1)

Publication Number Publication Date
ATE347599T1 true ATE347599T1 (de) 2006-12-15

Family

ID=8227261

Family Applications (1)

Application Number Title Priority Date Filing Date
AT98947427T ATE347599T1 (de) 1997-08-22 1998-08-12 Tuberkulose impfstoff

Country Status (13)

Country Link
US (1) US6673353B1 (enExample)
EP (2) EP0902086A1 (enExample)
JP (1) JP4255209B2 (enExample)
AT (1) ATE347599T1 (enExample)
AU (1) AU9435098A (enExample)
CA (1) CA2301879C (enExample)
CY (1) CY1106350T1 (enExample)
DE (1) DE69836588T2 (enExample)
DK (1) DK1007686T3 (enExample)
ES (1) ES2274580T3 (enExample)
PT (1) PT1007686E (enExample)
SI (1) SI1007686T1 (enExample)
WO (1) WO1999010496A1 (enExample)

Families Citing this family (33)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US8114414B2 (en) 1994-11-08 2012-02-14 The Trustees Of The University Of Pennsylvania Compositions and methods for treatment of cervical cancer
US8956621B2 (en) 1994-11-08 2015-02-17 The Trustees Of The University Of Pennsylvania Compositions and methods for treatment of cervical dysplasia
US6051237A (en) * 1994-11-08 2000-04-18 The Trustees Of The University Of Pennsylvania Specific immunotherapy of cancer using a live recombinant bacterial vaccine vector
US8791237B2 (en) 1994-11-08 2014-07-29 The Trustees Of The University Of Pennsylvania Compositions and methods for treatment of non-hodgkins lymphoma
US7820180B2 (en) * 2004-09-24 2010-10-26 The Trustees Of The University Of Pennsylvania Listeria-based and LLO-based vaccines
US7662396B2 (en) 2001-03-26 2010-02-16 The Trustees Of The University Of Pennsylvania Compositions and methods for enhancing the immunogenicity of antigens
US7794729B2 (en) 1994-11-08 2010-09-14 The Trustees Of The University Of Pennsylvania Methods and compositions for immunotherapy of cancer
WO2000026248A2 (en) 1998-11-04 2000-05-11 Isis Innovation Limited Tuberculosis diagnostic test
GB0006693D0 (en) * 2000-03-20 2000-05-10 Glaxo Group Ltd Vaccine
US9012141B2 (en) 2000-03-27 2015-04-21 Advaxis, Inc. Compositions and methods comprising KLK3 of FOLH1 antigen
AU2001255196A1 (en) * 2000-03-29 2001-10-08 The Trustees Of The University Of Pennsylvania Compositions and methods for enhancing immunogenicity of antigens
US6855320B2 (en) 2000-03-29 2005-02-15 The Trustees Of The University Of Pennsylvania Fusion of non-hemolytic, truncated form of listeriolysin O to antigens to enhance immunogenicity
US8771702B2 (en) 2001-03-26 2014-07-08 The Trustees Of The University Of Pennsylvania Non-hemolytic LLO fusion proteins and methods of utilizing same
US7700344B2 (en) 2001-03-26 2010-04-20 The Trustees Of The University Of Pennsylvania Compositions and methods for enhancing the immunogenicity of antigens
ES2382332T3 (es) * 2003-02-06 2012-06-07 Aduro Biotech Listeria atenuada para entrar en células no fagocíticas, vacunas que comprenden esta listeria y métodos de uso de las mismas
CN1798762B (zh) 2003-04-23 2010-04-28 马普科技促进协会 效能提高的结核病疫苗
EP1649869A1 (en) 2004-10-21 2006-04-26 Vakzine Projekt Management GmbH Combination of a recombinant mycobacterium and a biologically active agent as a vaccine
KR101329323B1 (ko) * 2004-12-01 2013-11-14 아에라스 글로벌 티비 백신 파운데이션 엔도솜을 이탈하는 능력이 보강된 재조합 비씨지 균주
US8268326B2 (en) 2006-08-15 2012-09-18 The Trustees Of The University Of Pennsylvania Compositions comprising HMW-MAA and fragments thereof, and methods of use thereof
US8241636B2 (en) 2006-08-15 2012-08-14 The Trustees Of The University Of Pennsylvania Compositions comprising HMW-MAA and fragments thereof, and methods of use thereof
US9017660B2 (en) 2009-11-11 2015-04-28 Advaxis, Inc. Compositions and methods for prevention of escape mutation in the treatment of Her2/neu over-expressing tumors
ES2741730T3 (es) 2008-05-19 2020-02-12 Advaxis Inc Sistema de administración doble para antígenos heterólogos que comprende una cepa de Listeria recombinante atenuada por la mutación de dal/dat y la deleción de ActA que comprende una molécula de ácido nucleico que codifica una proteína de fusión de listeriolisina O - antígeno prostático específico
US9650639B2 (en) 2008-05-19 2017-05-16 Advaxis, Inc. Dual delivery system for heterologous antigens
ES2637068T3 (es) 2009-03-04 2017-10-10 The Trustees Of The University Of Pennsylvania Composiciones que comprenden factores angiogénicos y métodos de uso de las mismas
US10016617B2 (en) 2009-11-11 2018-07-10 The Trustees Of The University Of Pennsylvania Combination immuno therapy and radiotherapy for the treatment of Her-2-positive cancers
SG188595A1 (en) 2010-09-20 2013-04-30 Vakzine Projekt Man Gmbh Recombinant mycobacterium as vaccine for use in humans
US9226958B2 (en) 2010-10-01 2016-01-05 University Of Georgia Research Foundation, Inc. Use of Listeria vaccine vectors to reverse vaccine unresponsiveness in parasitically infected individuals
WO2012085099A1 (en) 2010-12-21 2012-06-28 MAX-PLANCK-Gesellschaft zur Förderung der Wissenschaften e.V. Determination of the efficacy of an anti-mycobacterial vaccination
SI2654783T1 (sl) * 2010-12-21 2017-02-28 Max-Planck-Gesellschaft zur Fourderung der Wissenschaften e.V. Rekombinantni mycobacterium kot cepivo
AU2012229218B2 (en) 2011-03-11 2017-03-02 Advaxis, Inc. Listeria-based adjuvants
BR102012003790A2 (pt) 2012-02-17 2014-04-22 Fundacao Butantan Cepa de mycobacterium recombinante, composição imunogênica e uso
HK1205944A1 (en) 2012-03-12 2015-12-31 阿德瓦希斯公司 Suppressor cell function inhibition following listeria vaccine treatment
EP2834356A4 (en) * 2012-04-02 2015-09-02 Univ Arizona RECOMBINANT BACTERIUM FOR INDUCING A CELLULAR IMMUNE RESPONSE

Family Cites Families (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5504005A (en) * 1987-03-02 1996-04-02 Albert Einstein College Of Medicine Of Yeshiva University Recombinant mycobacterial vaccine

Also Published As

Publication number Publication date
DK1007686T3 (da) 2007-04-10
SI1007686T1 (sl) 2007-04-30
CA2301879A1 (en) 1999-03-04
EP0902086A1 (en) 1999-03-17
CA2301879C (en) 2014-02-04
US6673353B1 (en) 2004-01-06
WO1999010496A1 (en) 1999-03-04
PT1007686E (pt) 2007-03-30
EP1007686A1 (en) 2000-06-14
AU9435098A (en) 1999-03-16
EP1007686B1 (en) 2006-12-06
DE69836588D1 (de) 2007-01-18
CY1106350T1 (el) 2011-10-12
DE69836588T2 (de) 2007-04-05
ES2274580T3 (es) 2007-05-16
JP2001514000A (ja) 2001-09-11
JP4255209B2 (ja) 2009-04-15

Similar Documents

Publication Publication Date Title
ATE347599T1 (de) Tuberkulose impfstoff
ATE473238T1 (de) Tuberkulose vaccine mit verbesserter effizienz
BRPI9912663B1 (pt) vacina contra cáncer e polipeptìdeo.
ATE184052T1 (de) Gdf-1 und uog1 proteine
DK1025211T3 (da) Hyaluronansyntasegen og anvendelser deraf
ATE429504T1 (de) Proteinexpressionsvektor und benutzung desselbigen
DE69734882D1 (de) Dna immunisierung gegen chlamydia infektion
DE69930955D1 (de) Polypeptide mit lysophospholipaseaktivität und nukleinesäuren die sie kodieren
DE69840332D1 (de) Rekombinantes respiratorische synzytialvirus expressionssystem und impfstoffe
AU1013701A (en) Modified gp100 and uses thereof
DK251890D0 (da) Polypeptid og dets anvendelse samt ekspressionssystem til dets eksprimering
DE69230671D1 (de) Impfstoffe gegen actinobacillus pleuropneumonie
ATE183241T1 (de) Impstoff gegen streptococcus suis-infektion
NO983946D0 (no) Parapoksyviruser inneholdende fremmed DNA, fremstilling og anvendelse derav i vaksiner
ATE346931T1 (de) Clostridium perfringens impfstoff
BR0011469A (pt) Gm-csf equina
DK0919621T3 (da) Human TAK1 og DNA der koder derfor
CA2148369A1 (en) Actinobacillus pleuropneumoniae outer membrane lipoprotein a and uses thereof
FI902803A7 (fi) DNA-sekvenssi, joka koodaa a-amylaasi-pullulanaasientsyymiä
BR0013574A (pt) Antìgeno vacina de moraxella
DE60124380D1 (de) Angiogenese-assoziierte proteine und dafür kodierende nukleinsäure
ATE315646T1 (de) Leukocyten-aktivierender faktor
DE69530295D1 (de) Leishmania hauptprotein, dafür kodierende nukleinsaüre und verwendungen davon
BR0016740A (pt) Antìgenos de esporozoìto de cryptosporidium
MX9701904A (es) Proteinas de enlace de pka novedosas y usos de las mismas.

Legal Events

Date Code Title Description
UEP Publication of translation of european patent specification

Ref document number: 1007686

Country of ref document: EP